Scrip 100: R&D Paths Of Top 50 Pharma
How has R&D spending in the pharmaceutical industry changed over the last decade? While the R&D collective picture for Big Pharma may not have changed much, individual company stories differ markedly.
You may also be interested in...
CSL Ltd.'s sales grew 15% in its last fiscal year and are expected to grow about 8% in FY 2018, but the Australia-based company is looking beyond its plasma protein expertise to outside innovation to help boost future revenue.
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.